CubeBio Holdings Ltd

424B3 priced

EFFECT effective

F-4/A amended

Price $10.00 · 6,900,000 shares · Gross proceeds $69,000,000

F-4/A amended

6,900,000 shares

F-4/A amended

6,900,000 shares

F-4 filed

6,900,000 shares

DRS/A amended

CubeBio Holdings Ltd. reported a net loss of $6,805 for the year ended December 31, 2025, compared to a $29,753 loss for the period from inception (September 24, 2024) to December 31, 2024. The company remains a holding company with no operating revenue, relying on related-party transactions and financing. Key activities include the pending Business Combination Agreement with Mountain Crest Acquisition Corp. V, which aims to list the company on Nasdaq. The filing highlights ongoing liquidity challenges, with a going concern uncertainty due to cumulative losses and reliance on shareholder funding.

DRS/A amended

CubeBio Holdings Ltd's current filing highlights significant financial challenges, including substantial losses, negative cash flows, and reliance on external financing. The company has incurred a net loss of ₩8,065,334 thousand for 2024, with an accumulated deficit of ₩69,416,578 thousand. It has funded operations through equity and debt, but uncertainties around revenue generation and financing raise doubts about its ability to continue as a going concern. Recent activities include bond redemptions, treasury share sales, and leadership changes, such as the appointment of a new CEO.

DRS filed

CubeBio Holdings Ltd. is a biotechnology company focused on developing non-professional use products for early cancer screening, aiming to increase survival rates through broader access. The company has not generated revenue, with significant operating losses and negative cash flows, relying on equity and debt financing. Financial statements show increased operating expenses due to de-SPAC transaction costs and bond-related activities, while liquidity remains a concern with accumulated deficits and reliance on future funding. The company anticipates no near-term product revenue, dependent on regulatory approvals and commercialization of its product candidates.